Pathobiology 2027

Mechanisms of Disease

May 1-4, 2027

Flamingo Las Vegas, Las Vegas, NW

Session 033 – Investigative Pathology in Industry: Accelerating Translational Research and Drug Development with Artificial Intelligence and Computational Tools

3:00-4:45 PM
Sponsored by the ASIP Pathology in Biotech and Industry Scientific Interest Group
Session Room: TBD

Session Co-Chairs

Sripad Ram

Sripad Ram, PhD
Pfizer, Inc.

Cary Austin

Cary Austin, MD, PhD
Genentech, Inc.

Session Overview

This session will explore recent scientific and technological advances in digital pathology and computational tools for tissue evaluation in the biotechnology and pharma industry. Thought leaders from across the biopharmaceutical sector will provide attendees with an in-depth perspective on how artificial intelligence, machine learning, and foundation models are making an impact in automated pathology analysis and nonclinical safety evaluation, and will highlight some of the cutting-edge activities currently underway in investigative pathology within biotech and the pharmaceutical industry.

Agenda

  • Co-Chair – Welcome and Introductions

  • Lauren Himmel3:00-3:25 PM
    AI-Enabled Classification of Normal and Abnormal Tissues in Nonclinical Toxicity Studies
    Lauren Himmel, DVM, PhD
    Abbvie, Inc.

  • Lin Li3:25-3:50 PM
    Towards General-Purpose Pathology AI: Leveraging Foundation Models for Diverse Analysis Tasks
    Lin Li, MS
    Merck, Inc.

  • 3:50-4:15 PM
    AI-Powered Automatic Histopathologic Lesion Detection with Minimal Data Annotation
    Grace Zehnder, BS
    Genentech, Inc.

  • Sripad Ram4:15-4:45 PM
    Pathology in the Digital Era: Developing and Deploying Computational Tools for Nonclinical Safety Studies
    Sripad Ram, PhD
    Pfizer, Inc.